
Marta
Llanos Muñoz
Part Time Assistant Professor (Health Science)
Publications (57)
2023
-
Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 1, pp. 209-220
2022
-
Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study
European Thyroid Journal, Vol. 11, Núm. 5
-
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study
Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100
-
Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study
Cancers, Vol. 14, Núm. 24
2021
-
Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus
Pancreatology, Vol. 21, Núm. 1, pp. 215-223
-
Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma
Scientific Reports, Vol. 11, Núm. 1
-
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231
2019
-
Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group
Leukemia and Lymphoma
-
Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years
Leukemia and Lymphoma
-
Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma
PLoS ONE, Vol. 14, Núm. 2
-
Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group
Hematological Oncology
-
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 37, Núm. 28, pp. 2571-2580
2018
-
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)
Oncologist, Vol. 23, Núm. 4, pp. 422-432
-
First-line treatment outcomes according to cfDNA analysis of RAS mutation status in metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii183
-
Efficacy and safety of vandetanib for patients with advanced and progressive medullary thyroid cancer (MTC) as systemic treatment beyond first-line therapy
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii476
-
Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib
Oncotarget, Vol. 9, Núm. 97, pp. 36894-36905
2017
-
Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group
Cancer, Vol. 123, Núm. 19, pp. 3709-3716
-
Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group
Clinical Lymphoma, Myeloma and Leukemia, Vol. 17, Núm. 3, pp. 186-191
-
Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry
PLoS ONE, Vol. 12, Núm. 5
2015
-
Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors
Cancer and Metastasis Reviews, Vol. 34, Núm. 3, pp. 381-400